Guidance on nitrosamine impurities in medications updated
Health Canada updated its guidance on nitrosamine impurities in medications, republishing the document with a new update date of May 29, 2026. The establis…
Impact analysis · 40/100 · AI-assisted priority
This score prioritizes research; it does not predict an outcome. Method and limitations.
What happened
Health Canada updated its guidance on nitrosamine impurities in medications, republishing the document with a new update date of May 29, 2026. The established Acceptable Intake limits (Appendix 1) have been moved to a dedicated tab and updated with a new version published March 11, 2026.
Quantitative evidence
- Guidance update date: May 29, 2026
- AI limits version date: March 11, 2026
- Extent of changes to AI limits content
- Stakeholder response timeline
Affected entities
Analysis
The following contextual analysis is AI-assisted and separated from the reported primary-source record above.
Scientific context
The updated guidance presents revised Acceptable Intake limits for nitrosamine impurities, reflecting evolving toxicological risk assessment and the Carcinogenic Potency Categorization Approach. It reinforces testing and risk management expectations for manufacturing controls.
Market context
The update may impose compliance planning and testing cost burdens on market authorization holders but does not directly target any specific company.
Legal and regulatory context
This is a Health Canada guidance update, which is non‑binding policy rather than a legally enforceable regulation; affected entities must align risk assessments accordingly in quality change submissions.
Sources
For informational use only. Verify decisions against the linked regulator or primary source.
Evidence & limits
Source: Open the source record
- Record identifier
- a2c75e4ed3d1a3c0323360a9e8e23616eb3996170b4880f6fa87b3c5b7bebcb0
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- 2026-05-29T13:09:49Z
What it supports. The linked authority’s action, within the product, indication, jurisdiction, and procedural stage stated in that record.
Limits. A committee opinion, draft, or announcement does not by itself establish final authorization. The summary and contextual analysis are AI-assisted; a source link does not establish human review.
Connection basis. Related profiles are normalized name mentions in article text. A mention does not establish a legal relationship.